Key result
HeartMate LVADs are linked to significant thrombin generation and fibrinolysis versus unassisted end-stage HF.
Why the study?
Thromboembolic events complicate support with left ventricular assist devices, and the hematologic status of patients treated without anticoagulation is not fully understood.
Does HeartMate LVAD support activate coagulation and fibrinolytic pathways in patients with end-stage heart failure compared to those without LVAD?
Population
Patients with end-stage heart failure awaiting cardiac transplantation
Comparison
HeartMate LVAD without systemic anticoagulation vs patients not supported by assist device or anticoagulation
Design
Observational study
Authors
Loading...
May signal subclinical bleeding or thrombosis risk in HeartMate LVAD patients despite normal tests; leaves open whether specialized assays should guide management.
Observational
Does HeartMate LVAD support activate coagulation and fibrinolytic pathways in patients with end-stage heart failure compared to those without LVAD?
Patients with HeartMate LVADs exhibit subclinical activation of coagulation and fibrinolytic pathways despite normal standard coagulation tests, highlighting a potential risk for bleeding or thrombosis.
Spanier et al. (1996) conducted an observational in End-stage heart failure. HeartMate left ventricular assist device vs. End-stage heart failure without assist device or anticoagulation was evaluated on Thrombin generation and fibrinolysis. Patients supported with a HeartMate left ventricular assist device demonstrated significant thrombin generation and fibrinolysis compared to patients with end-stage heart failure without a device.